BuurT., LundbergM.Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients.Clin Nephrol1990; 34: 230–5.
2.
ShinabergerJ., MillerJ., GardenerP.Erythropoietin alert: risks of high hematocrit hemodialysis.Trans Am Soc Artif Inern Organs1988; 34: 179–84.
3.
CasatiS., PasseriniP., CampiseM.Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.Br Med J1987; 295: 1017–20.
4.
ZehnderC., GluckZ., DescoeudresC., UehlingerD., BlumbergA.Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis: secondary effects of the increase of haemoglobin.Nephrol Dial Transplant1988; 3: 657–60.
5.
VanGeelenJ., NubeM., ZuurbierP.Influence of erythropoietin treatment on urea kinetic parameters in hemodialysis patients.Clin Nephrol1991; 35: 165–70.
6.
BaranyP., PetterssonE., AhlbergM., HultmanE., BergstromJ.Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin.Clin Nephrol1991; 35: 270–9.
7.
EschbachJ., AbsulhadiM., BrowneJ., DelanoB.Recombinant human erythropoietin in anemic patients with end-stage renal disease.Ann Intern Med1989; 111: 992–1000.
8.
KaupkeC., VaziriN., SampsonJ., AtkinsK.Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients.Int J Artif Organs1990; 13: 218–22.
9.
SpinowitzB., ArslanianJ., CharytanC., GoldenR., RascoffJ., GallerM.Impact of epoetin beta on dialyzer clearance and heparin requirements.Am J Kidney Dis1991; 18: 668–73.
10.
BennetW.A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease.J Am Soc Nephrol1991; 1: 990–8.
11.
DelanoB.Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.Am J Kidney Dis1989; 14: 14–8.
12.
EschbachJ., EgrieJ., DowningM., BrowneJ., AdamsonJ.Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.N Engl J Med1987; 316: 73–8.
13.
Quinn-CefaroR., LundinA., DelanoB., FriedmanE.Subjective benefits of recombinant human erythropoietin in hemodialysis patients.Dial Transpl1989; 18: 444–6.
14.
CanaudB., Polito-BoulouxC., GarredL.Recombinant human erythropoietin: 18 months experience in hemodialysis patients.Am J Kidney Dis1990; 15: 169–75.
15.
BennetS., EdmundsM., FeehallyJ., WallsJ.Nutritional status of hemodialysis patients receiving recombinant human erythropoietin therapy.J Renal Nutrition1991; 1: 125–9.
16.
MatO., StolearJ., GeorgesB.Blood lipid profile in hemodialysis patients treated with human erythropoietin.Nephron1992; 60: 236–7.
17.
VironB., DonsimoniR., MichelC., AI KhayatR., MignonF.Effect of recombinant human erythropoietin on nutritional status and plasma lipids in uremic patients.Nephron1992; 60: 249.
18.
PrataM., SousaF., BarbasJ., RodriguesM.Blood lipids in haemodialysis patients treated with erythropoietin.Nephrol Dial Transplant1990; 5: 474.
19.
RiedelE., HamplH., ScigallaP., NundelM., KesselM.Correction of amino acid metabolism by recombinant human erythropoietin therapy in hemodialysis patients.Kidney Int1989; 36: 216–21.
20.
HakimR., StivelmanJ., SchulmanG.Iron overload and mobilization in long-term hemodialysis patients.Kidney Int1990; 10: 293–8.
21.
McCarthyJ., JohnsonW., NixonD.Transfusional iron overload in patients undegoing dialysis: treatment with erythropoietin and phlebotomy.J Lab Clin Med1989; 114: 193–9.
22.
VanWyckD., StivelmanJ., RuizJ.Iron status in patients receiving erythropoietin for dialysis-associated anemia.Kidney Int1989; 35: 712–6.
23.
VanWyckD.The challenge of iron deficiency during r-HuEPO therapy.Sem Dial1989; 2: 135–6.
